Carl Johnson is a Senior Scientist at Regeneron, with a robust background in oncology research and development, particularly in CAR-T/TCR immunotherapies. Prior to Regeneron, Carl held various roles at 2seventy bio, advancing from Senior Associate Scientist I to Principal Associate Scientist I, focusing on evaluating novel targets and ensuring target safety through in-vitro de-risking. Carl's experience spans several positions at bluebird bio and Brigham and Women's Hospital, where contributions included managing laboratory operations and researching Notch signaling in cancer. Carl earned a Master of Science in Applied Molecular Biotechnology and a Bachelor of Science in Biology from the University of Massachusetts Amherst.
This person is not in the org chart
This person is not in any teams
This person is not in any offices